Vincent Gnanapragasam

University Lecturer in Uro-oncology

Vincent Gnanapragasam

Honorary Consultant Urologist
Chair of the Urology Research and Development Committee

Direct:
+44 (0)1223 274316email
NHS Secretary:
+44 (0)1223 586819email
Private Secretary:
+44 (0)1223 266927 (Cambridge Urology Clinic)email
Special Interests:

Prostate cancer, general urology, translational research and clinical trials in uro-oncology, robotic prostatectomy

Profile

Vincent is an academic urological surgeon with an interest in basic and translational research in prostate cancer. He has a specific remit to set up clinical trials in prostate cancer to look at ways of improving the outcomes for men with high risk disease and identify new targets for novel therapy. He has been trained in open prostatectomy in the North East and robotic prostatectomy in Paris and Cambridge.

 

Publications

1: Comparative oncological and toxicity outcomes of salvage radical prostatectomy versus non- surgical therapies for radio-recurrent prostate cancer: A meta-regression analysis. YPhilippou,  RA Parker, D Volanisc, VJ Gnanapragasam Eur Urol Focus (2016) (In Press) 

 2: Wadhwa K, Carmona-Echeveria L, Kuru T, Gaziev G, Serrao E, Parashar D, Frey J, Dimov I, Seidenader J, Acher P, Muir G, Doble A, Gnanapragasam V, Hadaschik B, Kastner C. Transperineal prostate biopsies for diagnosis of prostate cancer are well tolerated: a prospective study using patient-reported outcome measures. Asian J Androl. 2016 Feb 26. doi: 10.4103/1008-682X.173453. [Epub ahead of print] PubMed PMID: 26924279.

3: Bruinsma SM, Bangma CH, Carroll PR, Leapman MS, Rannikko A, Petrides N, Weerakoon M, Bokhorst LP, Roobol MJ; Movember GAP3 consortium. Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol. 2016 Mar;13(3):151-67. doi: 10.1038/nrurol.2015.313. Epub 2016 Jan 27. Review. PubMed PMID: 26813955.

 4: Barrett T, Priest AN, Lawrence EM, Goldman DA, Warren AY, Gnanapragasam VJ, Sala E, Gallagher FA. Ratio of Tumor to Normal Prostate Tissue Apparent Diffusion Coefficient as a Method for Quantifying DWI of the Prostate. AJR Am J Roentgenol. 2015 Dec;205(6):W585-93. doi: 10.2214/AJR.15.14338. PubMed PMID: 26587948.

 5: Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Grönberg H, Neal DE; CamCaP Study Group. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine. 2015 Jul 29;2(9):1133-44. doi: 10.1016/j.ebiom.2015.07.017. eCollection 2015
Sep. PubMed PMID: 26501111; PubMed Central PMCID: PMC4588396.

 6: Barrett T, Patterson AJ, Koo BC, Wadhwa K, Warren AY, Doble A, Gnanapragasam VJ, Kastner C, Gallagher FA. Targeted transperineal biopsy of the prostate has limited additional benefit over background cores for larger MRI-identified tumors. World J Urol. 2016 Apr;34(4):501-508. Epub 2015 Aug 4. PubMed PMID: 26238348.

 7: Philippou Y, Raja H, Gnanapragasam VJ. Active surveillance of prostate cancer: a questionnaire survey of urologists, clinical oncologists and urology nurse specialists across three  ancer networks in the United Kingdom. BMC Urol. 2015 Jun 13;15:52. doi: 10.1186/s12894-015-0049-y. PubMed PMID: 26070313; PubMed Central PMCID: PMC4465007.

 8. Gundem G, Van Loo P, Kremeyer B, Alexandrov B, Tubio JM, Papaemmanuil E, Bewer DS, Kallio HM, Högnäs G, Annala M, Kvinummi K, Goody V, Latimer C, OMeara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nkter M, Foster C, Kote-Jarai Z, Eston D, Whitaker HC; ICGC Prostate UK Group, Nal DE, Cooper CS, Eeles RA, Vsakorpi T, Campbell PJ, McDermott U, Wedge DC, Bva GS. The evolutionary hstory of lethal metastatic prostate cancer. Nture. 2015 Apr16;520(7547):353-7. doi: 10.1038/nature14347. Epub 2015 Apr 1. PubMed PMID: 25830880; PubMed Central PMCID: PMC4413032.

 9: Hong MK, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, Alexandrov LB, Sloggett C, Cmero M, Marass F, Tsui D, Mangiola S, Lonie A, Naeem H, Sapre N, Phal PM, Kurganovs N, Chin X, Kerger M, Warren AY, Neal D, Gnanapragasam V, Rosenfeld N, Pedersen JS, Ryan A, Haviv I, Costello AJ, Corcoran NM, Hovens CM. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 2015 Apr 1;6:6605. doi: 10.1038/ncomms7605. PubMed PMID: 25827447; PubMed Central PMCID: PMC4396364.

 10: Greenberg DC, Lophatananon A, Wright KA, Muir KR, Gnanapragasam VJ. Trends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population. PLoS One. 2015 Mar5;10(3):e0119494. doi: 10.1371/journal.pone.0119494. eCollection 2015. PubMed PMID: 25742020; PubMed Central PMCID: PMC4351083.

 11: Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, Dennis N, Merson S, Leongamornlert D, Zamora J, Corbishley C, Thomas S, Nik-Zainal S, Ramakrishna M, O’Meara S, Matthews L, Clark J, Hurst R, Mithen R, Bristow RG, Boutros PC, Fraser M, Cooke S, Raine K, Jones D, Menzies A, Stebbings L, Hinton J, Teague J, McLaren S, Mudie L, Hardy C, Anderson E, Joseph O, Goody V, Robinson B, Maddison M, Gamble S,  reenman C, Berney D, Hazell S, Livni N; ICGC Prostate Group, Fisher C, Ogden C, Kumar P, Thompson A, Woodhouse C, Nicol D, Mayer E, Dudderidge T, Shah NC, Gnanapragasam
V, Voet T, Campbell P, Futreal A, Easton D, Warren AY, Foster CS, Stratton MR, Whitaker HC, McDermott U, Brewer DS, Neal DE. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet. 2015 Apr;47(4):367-72. doi: 10.1038/ng.3221. Epub 2015 Mar 2. Erratum in: Nat Genet. 2015 Jun;47(6):689. PubMed PMID: 25730763; PubMed Central PMCID: PMC4380509.

 12: Connolly SS, Raja A, Stunell H, Parashar D, S, Warren AY, Gnanapragasam VJ, Eisen T. Diagnostic accuracy of preoperative computed tomography used alone to detect lymph-node
involvement at radical nephrectomy. Scand J Urol. 2015 Apr;49(2):142-8. doi: 10.3109/21681805.2014.969307. Epub 2015 Jan 26. PubMed PMID: 25623950. 

13: Gnanapragasam VJ, Payne H, Syndikus I, Kynaston H Johnstone T. Primary radical therapy selection in high-risk non-metastatic prostate cancer. Clin Oncol (R Coll Radiol). 2015 Mar;27(3):136-44. doi:10.1016/j.clon.2014.11.004. Epub 2014 Nov 28. Review. PubMed PMID: 25441052.

 14: Kachroo N, Warren AY, Gnanapragasam VJ. Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men. BMC Cancer. 2014 Sep 16;14:673. doi: 10.1186/1471-2407-14-673. PubMed PMID: 25227682; PubMed Central PMCID: PMC4174634.

 15: Lawrence EM, Gallagher FA, Barrett T, Warren AY, Priest AN, Goldman DA, Sala E, Gnanapragasam VJ. Preoperative 3-T diffusion-weighted MRI for the qualitative a quantitative assessment of extracapsular etension in patients with intermediate- or high-risk prostate cancer. AJR A J Roentgenol. 2014 ep;203(3):W280-6. doi: 10.2214/AJR.13.11754. PID: 25148185.

 16: Gnanapragasam VJ. Molecular markers to guide pimary radical treatmentselection in localized prostate cancer. ExpertRev Mol Diagn. 2014Sep;14(7):871-81. doi:10.1586/14737159.2014.936851. Epub 2014 Jul 4. Review.PubMed PMID: 24994559.

 17: Volanis D, Neal DE, Warren AY, GnanapragasamVJ. Incidence of needle-tractseeding following prostate biopsy for suspectedcancer: a review of theliterature. BJU Int. 2015 May;115(5):698-704.doi: 10.1111/bju.12849. Epub 2014Oct 22. Review. PubMed PMID: 24958224.

 18: Lawrence EM, Tang SY, Barrett T, Koo B,Goldman DA, Warren AY, Axell RG,Doble A, Gallagher FA, Gnanapragasam VJ, KastnerC, Sala E. Prostate cancer:performance characteristics of combined T₂W andDW-MRI scoring in the setting oftemplate transperineal re-biopsy using MR-TRUSfusion. Eur Radiol. 2014ul;24(7):1497-505. doi:
10.1007/s00330-014-3159-0. Epub 2014 Apr 18. PubMedPMID: 24744197.

 19.Shaw GL, Thomas BC, Dawson SN, Srivastava G,Vowler SL, Gnanapragasam VJ,Shah NC, Warren AY, Neal DE. Identification ofpathologically insignificantrostate cancer is not accurate in unscreenedmen. Br J Cancer. 2014 May13;110(10):2405-11. doi: 10.1038/bjc.2014.192.Epub 2014 Apr 10. PubMed PMID:24722183; PubMed Central PMCID: PMC4021526.

 20: Greenberg DC, Wright KA, Lophathanon A, MuirKR, Gnanapragasam VJ. Changingpresentation of prostate cancer in a UKpopulation–10 year trends in prostatecancer risk profiles in the East of England. Br JCancer. 2013 Oct15;109(8):2115-20. doi: 10.1038/bjc.2013.589.Epub 2013 Sep 26. PubMed PMID:24071596; PubMed Central PMCID: PMC3798976.

 21: Lee LS, Thiruneelakandasivam S, Hong MK,Peters JS, Warren A, Mills R,Greenberg D, Wright K, Gnanapragasam V. Aretransrectal prostate biopsiesroutinely indicated in patients th incidentallydiagnosed prostate cancerfollowing transurethral resection of the prostatefor benign disease? Urol Int.2013;91(4):397-403. doi: 10.1159/000350898. Epub2013 Aug 1. PubMed PMID:23921216.

 22: Gnanapragasam VJ. To treat or not to treat:is the way forward clearer inlow-risk prostate cancer? BJU Int. 2013Aug;112(3):285-7. doi:10.1111/j.1464-410X.2012.11723.x. Epub 2013 Mar7. PubMed PMID: 23469893.

 23:Nelson AW, Harvey RC, Parker RA, Kastner C,Doble A, Gnanapragasam VJ. Repeatprostate biopsy strategies after initial negativebiopsy: meta-regressioncomparing cancer detection of transperineal,transrectal saturation and MRIguided biopsy. PLoS One. 2013;8(2):e57480. doi:10.1371/journal.pone.0057480.Epub 2013 Feb 27. PubMed PMID: 23460864; PubMed
Central PMCID: PMC3583836.

 24: Kachroo N, Gnanapragasam VJ. The role oftreatment modality on the utility ofpredictive tissue biomarkers in clinical prostatecancer: a systematic review. JCancer Res Clin Oncol. 2013 Jan;139(1):1-24. doi:10.1007/s00432-012-1351-7. Epub2012 Nov 28. Review. PubMed PMID: 23187933.

 25: Kachroo N, Valencia T, Warren AY,Gnanapragasam VJ. Evidence fordownregulation of the negative regulator SPRED2in clinical prostate cancer. Br JCancer. 2013 Feb 19;108(3):597-601. doi:10.1038/bjc.2012.507.

The cookie setting on this website is set to ‘allow cookies’ to give you the very best experience.

If you continue without changing this setting, you consent to this - but if you want, you can change your setting at any time using the ‘change cookie setting’ link at the bottom of this page.

Cookie Setting







Our Cookies

Cookie NamePurpose
eu_ask This is used to store the cookie setting you set in the form above.
If you choose 'Do Not Allow Cookies' we will need to store this information as a cookie with the value N.
If you choose 'Allow Cookies' or do not make a choice, we will store this information as a cookie with the value Y.

The value is kept for one year.

3rd Party Cookies

Cookie NamePurpose
Google Analytics This website uses Google Analytics, a web analytics service provided by Google, Inc.
Google Analytics sets a cookie in order to evaluate your use of the website and compile reports for us on activity on the website.
Google stores the information collected by the cookie on servers in the United States.
Google may also transfer this information to third parties where required to do so by law,
or where such third parties process the information on Google's behalf.
Google will not associate your IP address with any other data held by Google
By using this website, you consent to the processing of data about you by Google in the manner and for the purposes set out above.

How to reject or delete this cookie

http://www.google.com/intl/en/privacypolicy.html